SCHEMBL5743568

SCHEMBL5743568

CCc1cc(CO[Si](C)(C)C(C)(C)C)cc(NC(=O)O)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
NPC1 O15118 3/20 0.33
RAB9A P51151 3/20 0.33
TACR1 P25103 1/20 0.33
CNR2 P34972 1/20 0.33
LMNA P02545 2/20 0.33
TDP1 Q9NUW8 1/20 0.32
KCNH2 Q12809 1/20 0.32
SMN1; SMN2 Q16637 5/20 0.32
BACE1 P56817 1/20 0.32
CHRNB2 P17787 1/20 0.32
CHRNB4 P30926 1/20 0.32
CHRNA3 P32297 1/20 0.32
CHRNA4 P43681 1/20 0.32
KDM4E B2RXH2 3/20 0.31
MAPT P10636 3/20 0.31
ALDH1A1 P00352 1/20 0.31
ADORA3 P0DMS8 1/20 0.31
ADORA1 P30542 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5742388 0.88 MAPKAPK2 (0.39)
SCHEMBL5745127 0.85 USP14 (0.34) KMT2AMEN1NPC1RAB9ATACR1
SCHEMBL22689537 0.78 BACE1 (0.35) KMT2AMEN1TACR1BACE1KDM4E
SCHEMBL4505482 0.77 PDE5A (0.42) KMT2AMEN1NPC1RAB9ALMNA
SCHEMBL4510215 0.76 DEGS1 (0.42) KMT2AMEN1NPC1RAB9ALMNA
SCHEMBL21158927 0.75 CA12 (0.30)
SCHEMBL5744173 0.75 NOS2 (0.45)
SCHEMBL19306519 0.75 KLK7 (0.41) KMT2AMEN1NPC1RAB9ASMN1; SMN2
SCHEMBL17161617 0.75 BACE1 (0.33) NPC1RAB9ATACR1BACE1KDM4E
SCHEMBL2799997 0.74 SMN1; SMN2 (0.43) NPC1RAB9ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1404672-B1 TYROSINE KINASE INHIBITORS MERCK & CO INC (US) 2006-01-18 EP disclosed
US-6875767-B2 (5-cyano-2-thiazolyl)amino-4-pyridine tyrosine kinase inhibitors MERCK & CO., INC. (US) 2005-04-05 US disclosed
EP-1404672-A1 TYROSINE KINASE INHIBITORS Merck & Co., Inc. (US) 2004-04-07 EP disclosed
US-20030100567-A1 Tyrosine kinase inhibitors MERCK & CO., INC. 2003-05-29 US disclosed
WO-2003000687-A1 TYROSINE KINASE INHIBITORS MERCK & CO., INC. (US) 2003-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100567-A1 Tyrosine kinase inhibitors ERBB2, TYRO3, TIE1 KMT2A 3298/4885MEN1 4406/4885NPC1 3497/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.